Edwards Lifesciences Corporation Proceeds from Lines of Credit
Edwards Lifesciences Corporation (EW) reported Proceeds from Lines of Credit of $705.10 million for the 9-month period ending 2013-09-30, per its 10-Q filed 2013-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2013-11-07
- Edwards Lifesciences Corporation proceeds from lines of credit for the quarter ending 2013-09-30 was $372.90M, a 1036.89% increase year-over-year.
- Edwards Lifesciences Corporation proceeds from lines of credit for the quarter ending 2013-06-30 was $168.40M, a 214.77% increase year-over-year.
- Edwards Lifesciences Corporation proceeds from lines of credit for the quarter ending 2013-03-31 was $163.80M, a 8.05% increase year-over-year.
- Edwards Lifesciences Corporation proceeds from lines of credit for the quarter ending 2012-12-31 was $169.10M, a 720.87% increase year-over-year.
- Edwards Lifesciences Corporation proceeds from lines of credit for fiscal 2012 was $407.00M, a 22.64% decline from fiscal 2011.
- Edwards Lifesciences Corporation proceeds from lines of credit for fiscal 2011 was $526.10M, a 106.80% increase from fiscal 2010.
- Edwards Lifesciences Corporation proceeds from lines of credit for fiscal 2010 was $254.40M, a 96.75% increase from fiscal 2009.
- Edwards Lifesciences Corporation proceeds from lines of credit for fiscal 2009 was $129.30M, a 37.32% decline from fiscal 2008.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2013-09-30 | $372.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $541.30M derived: sum of 2 quarters · filed 2013-11-07 | $705.10M 10-Q · filed 2013-11-07 | $874.20M derived: sum of 4 quarters · filed 2013-11-07 |
| 2013-06-30 | $168.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $332.20M 10-Q · filed 2013-08-06 | $501.30M derived: sum of 3 quarters · filed 2013-08-06 | $534.10M derived: sum of 4 quarters · filed 2013-11-07 |
| 2013-03-31 | $163.80M 10-Q · filed 2013-05-06 | $332.90M derived: sum of 2 quarters · filed 2013-05-06 | $365.70M derived: sum of 3 quarters · filed 2013-11-07 | $419.20M derived: sum of 4 quarters · filed 2013-11-07 |
| 2012-12-31 | $169.10M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $201.90M derived: sum of 2 quarters · filed 2013-11-07 | $255.40M derived: sum of 3 quarters · filed 2013-11-07 | $407.00M 10-K · filed 2013-02-28 |
| 2012-09-30 | $32.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $86.30M derived: sum of 2 quarters · filed 2013-11-07 | $237.90M 10-Q · filed 2013-11-07 | $258.50M derived: sum of 4 quarters · filed 2013-11-07 |
| 2012-06-30 | $53.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $205.10M 10-Q · filed 2013-08-06 | $225.70M derived: sum of 3 quarters · filed 2013-08-06 | $530.70M derived: sum of 4 quarters · filed 2013-08-06 |
| 2012-03-31 | $151.60M 10-Q · filed 2013-05-06 | $172.20M derived: sum of 2 quarters · filed 2013-05-06 | $477.20M derived: sum of 3 quarters · filed 2013-05-06 | $567.20M derived: sum of 4 quarters · filed 2013-05-06 |
| 2011-12-31 | $20.60M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $325.60M derived: sum of 2 quarters · filed 2013-02-28 | $415.60M derived: sum of 3 quarters · filed 2013-02-28 | $526.10M 10-K · filed 2013-02-28 |
| 2011-09-30 | $305.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $395.00M derived: sum of 2 quarters · filed 2012-11-07 | $505.50M 10-Q · filed 2012-11-07 | $543.10M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-06-30 | $90.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $200.50M 10-Q · filed 2012-08-07 | $238.10M derived: sum of 3 quarters · filed 2013-02-28 | $266.70M derived: sum of 4 quarters · filed 2013-02-28 |
| 2011-03-31 | $110.50M 10-Q · filed 2012-05-09 | $148.10M derived: sum of 2 quarters · filed 2013-02-28 | $176.70M derived: sum of 3 quarters · filed 2013-02-28 | $260.40M derived: sum of 4 quarters · filed 2013-02-28 |
| 2010-12-31 | $37.60M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $66.20M derived: sum of 2 quarters · filed 2013-02-28 | $149.90M derived: sum of 3 quarters · filed 2013-02-28 | $254.40M 10-K · filed 2013-02-28 |
| 2010-09-30 | $28.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $112.30M derived: sum of 2 quarters · filed 2011-11-08 | $216.80M 10-Q · filed 2011-11-08 | |
| 2010-06-30 | $83.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | $188.20M 10-Q · filed 2011-08-08 | ||
| 2010-03-31 | $104.50M 10-Q · filed 2011-05-09 | |||
| 2009-12-31 | $129.30M 10-K · filed 2012-02-27 | |||
| 2008-12-31 | $206.30M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |